Roic AI
Search
/
Search
/
Pricing
Sign inSign up

You're using the beta version. You're using the beta version of the new website.

SummaryFinancialsRatiosTranscriptsClassic View

Footer

Found an error or have an idea?
or write us an email to [email protected]

Company

  • About
  • Pricing
  • Blog

Support

  • Knowledge Base
  • FAQ

Legal

  • Privacy Policy

© 2023 Roic AI, Inc. All rights reserved.

  1. United States Stocks
  2. •

    Healthcare
  3. •

    Biotechnology
Crinetics Pharmaceuticals, Inc. logo

Crinetics Pharmaceuticals, Inc.

CRNX US

CRNX USCrinetics Pharmaceuticals, Inc.USUS
FIGI: BBG00BC59224
Business
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego, California.

28.82

USD
-0.35
(-1.20%)
-3.41EPS Dil.
-8.45P/E
1.58BMarket Cap
Crinetics Pharmaceuticals, Inc.
CRNX
(United States Composite)

Recent

price

28.82

P/E

ratio

-8.45

div

yld

- -

ROIC.AI

Legends:
Stock price
0.86
Beta (1.0 Market)
% total return 09/23
Stock
S&P500
YTD
60.63
- -
3Y
114.17
- -
5Y
- -
- -

Company News

  • Dow Jones Newswires

    11 days ago

    Crinetics Pharmaceuticals Shares Rise 17% After Soaring Monday

  • Investor's Business Daily

    12 days ago

    Crinetics Pharmaceuticals Just Scored A Much-Needed Win And Soared 63%

  • MarketWatch.com

    12 days ago

    Tesla and Canopy Growth stocks surge, RTX and J.M. Smucker shares fall, and other stocks on the move

  • Dow Jones Newswires

    12 days ago

    Crinetics Shares Surge Premarket on Phase 3 Paltusotine Success >CRNX

  • Dow Jones Newswires

    a month ago

    Crinetics Pharmaceuticals 2Q Loss/Shr 94c >CRNX

  • Dow Jones Newswires

    5 months ago

    Crinetics Pharmaceuticals 1Q Loss/Shr 85c >CRNX

- -
- -
- -
- -
- -
- -
- -
- -
- -
2016
2017
2018
2019
2020
2021
2022
TTM
USD
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.03
0.09
0.09
Revenue per ShareRevenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.43
-0.66
-2.23
-2.09
-2.42
-2.80
-3.15
-3.41
Basic EPS, GAAPBasic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.41
-0.70
-1.69
-1.94
-2.04
-2.32
-2.25
-2.99
Free Cash Flow per Basic ShareFree Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per ShareDividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.32
-0.74
-1.80
4.82
5.12
6.98
5.94
4.68
Book Value per ShareBook Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.28
-0.68
6.66
4.83
5.12
6.97
5.87
4.65
Tangible Book Value per ShareTangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
14
14
12
24
30
38
52
54
Basic Weighted Avg SharesBasic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
5
5
Sales/Revenue/TurnoverSales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-9,990.91
-3,544.06
-3,971.51
Operating Margin (%)Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
0
0
0
1
1
1
1
1
Depreciation ExpenseDepreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
-6
-9
-27
-50
-74
-108
-164
-184
Net Income, GAAPNet Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-9,985.25
-3,460.38
-3,804.10
Profit Margin (%)Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
11
14
159
115
167
329
317
252
Working CapitalWorking Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
0
- -
- -
5
4
3
2
1
LT DebtLT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
-6
-15
160
117
169
332
316
254
Total EquityTotal Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-51.64
-42.95
-50.24
-56.97
Return on Common Equity (%)Return on Common Equity (%)
Capital Structure
USD

•

in mil. unless spec.
Dec'22
Mar'19
Jun'19
ST Debt
- -
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
54
54
55
Market Capitalization
- -
867
985
Growth Rates
USD

•

in mil. unless spec.
(avg. rate of change)
10 years
5 years
1 year
Sales/Revenue/Turnover
- -
- -
400.00%
Net Income, GAAP
-NaN%
-86.20%
-51.85%
Free Cash Flow
-NaN%
-68.15%
-31.46%
Total Cash Common Dividend
- -
- -
- -
Total Equity
-NaN%
-211.49%
-4.82%
Quarterly Revenue
USD

•

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
1
1
2022
3
0
0
1
5
Quarterly Earnings Per Share
USD

•

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2020
- -
- -
-0.56
-0.66
-2.42
2021
-0.69
-0.70
-0.73
-0.68
-2.80
2022
-0.73
-0.81
-0.78
-0.84
-3.15
Quarterly Dividends Per Share
USD

•

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Working Capital
USD

•

in mil. unless spec.
Dec'22
Mar'19
Jun'19
Total Current Assets
345
305
285
Cash, Cash Equivalents & STI
334
296
265
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
28
26
33
Payables & Accruals
15
16
21
ST Debt
- -
1
1
Deferred Revenue
2
2
2